Foursan Group Announces the Exit of its Investment in Hikma Pharmaceauticals PLC

Printer-friendly versionSend to friend

Foursan Group, a leading Middle Eastern private equity firm, announced today the completion of a successful exit of its stake in Hikma Pharmaceuticals PLC, one of the region’s leading pharmaceutical companies with operations in the Middle East and North Africa, US and Europe. Foursan was initially invested through its Jordan Fund in Arab Pharmaceutical Manufacturing Company, which was acquired by Hikma.

Commenting on the transaction, Nashat T. Masri, a Partner with Foursan Group, stated: “We are pleased with this transaction and the attractive returns we generated for our investors in the Jordan Fund. Hikma is a leading pharmaceutical company and we wish it all the best in its future endeavors.”